77 related articles for article (PubMed ID: 19361285)
21. Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway.
Ikeda Z; Kamei T; Sasaki Y; Reynolds M; Sakai N; Yoshikawa M; Tawada M; Morishita N; Dougan DR; Chen CH; Levin I; Zou H; Kuno M; Arimura N; Kikukawa Y; Kondo M; Tohyama K; Sato K
J Med Chem; 2023 May; 66(9):6354-6371. PubMed ID: 37120845
[TBL] [Abstract][Full Text] [Related]
22. The role of the lys628 (192) residue of the complement protease, c1s, in interacting with Peptide and protein substrates.
Wijeyewickrema LC; Duncan RC; Pike RN
Front Immunol; 2014; 5():444. PubMed ID: 25278939
[TBL] [Abstract][Full Text] [Related]
23. Distributions of enzyme residues yielding mutants with improved substrate specificities from two different directed evolution strategies.
Paramesvaran J; Hibbert EG; Russell AJ; Dalby PA
Protein Eng Des Sel; 2009 Jul; 22(7):401-11. PubMed ID: 19502357
[TBL] [Abstract][Full Text] [Related]
24. Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4.
Swedberg JE; Nigon LV; Reid JC; de Veer SJ; Walpole CM; Stephens CR; Walsh TP; Takayama TK; Hooper JD; Clements JA; Buckle AM; Harris JM
Chem Biol; 2009 Jun; 16(6):633-43. PubMed ID: 19549601
[TBL] [Abstract][Full Text] [Related]
25. Unconjugated bilirubin inhibits C1 esterase activity.
Arriaga SM; Basiglio CL; Mottino AD; Almará AM
Clin Biochem; 2009 Jun; 42(9):919-21. PubMed ID: 19150444
[TBL] [Abstract][Full Text] [Related]
26. Structure-based analysis of inhibitor binding to Ht-d.
Botos I; Scapozza L; Shannon JD; Fox JW; Meyer EF
Acta Crystallogr D Biol Crystallogr; 1995 Jul; 51(Pt 4):597-604. PubMed ID: 15299848
[TBL] [Abstract][Full Text] [Related]
27. Phage display screening against a set of targets to establish peptide-based sugar mimetics and molecular docking to predict binding site.
Yu L; Yu PS; Yee Yen Mui E; McKelvie JC; Pham TP; Yap YW; Wong WQ; Wu J; Deng W; Orner BP
Bioorg Med Chem; 2009 Jul; 17(13):4825-32. PubMed ID: 19447041
[TBL] [Abstract][Full Text] [Related]
28. Subsite substrate specificity of midgut insect chymotrypsins.
Sato PM; Lopes AR; Juliano L; Juliano MA; Terra WR
Insect Biochem Mol Biol; 2008 Jun; 38(6):628-33. PubMed ID: 18510974
[TBL] [Abstract][Full Text] [Related]
29. Structural mechanisms of inactivation in scabies mite serine protease paralogues.
Fischer K; Langendorf CG; Irving JA; Reynolds S; Willis C; Beckham S; Law RH; Yang S; Bashtannyk-Puhalovich TA; McGowan S; Whisstock JC; Pike RN; Kemp DJ; Buckle AM
J Mol Biol; 2009 Jul; 390(4):635-45. PubMed ID: 19427318
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of recombinant caspase specificity by competitive substrates.
Benkova B; Lozanov V; Ivanov IP; Mitev V
Anal Biochem; 2009 Nov; 394(1):68-74. PubMed ID: 19595985
[TBL] [Abstract][Full Text] [Related]
31. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
32. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
[TBL] [Abstract][Full Text] [Related]
33. A library of fluorescent peptides for exploring the substrate specificities of prolyl isomerases.
Zoldák G; Aumüller T; Lücke C; Hritz J; Oostenbrink C; Fischer G; Schmid FX
Biochemistry; 2009 Nov; 48(43):10423-36. PubMed ID: 19785464
[TBL] [Abstract][Full Text] [Related]
34. Activation loop 3 and the 170 loop interact in the active conformation of coagulation factor VIIa.
Persson E; Olsen OH
FEBS J; 2009 Jun; 276(11):3099-109. PubMed ID: 19490111
[TBL] [Abstract][Full Text] [Related]
35. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
[TBL] [Abstract][Full Text] [Related]
36. Characterization of protein impurities and site-specific modifications using peptide mapping with liquid chromatography and data independent acquisition mass spectrometry.
Xie H; Gilar M; Gebler JC
Anal Chem; 2009 Jul; 81(14):5699-708. PubMed ID: 19518054
[TBL] [Abstract][Full Text] [Related]
37. Domain Interaction Footprint: a multi-classification approach to predict domain-peptide interactions.
Schillinger C; Boisguerin P; Krause G
Bioinformatics; 2009 Jul; 25(13):1632-9. PubMed ID: 19376827
[TBL] [Abstract][Full Text] [Related]
38. Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition.
Lai H; Feng M; Roxas-Duncan V; Dakshanamurthy S; Smith LA; Yang DC
Arch Biochem Biophys; 2009 Nov; 491(1-2):75-84. PubMed ID: 19772855
[TBL] [Abstract][Full Text] [Related]
39. NMR study of complexes between low molecular mass inhibitors and the West Nile virus NS2B-NS3 protease.
Su XC; Ozawa K; Yagi H; Lim SP; Wen D; Ekonomiuk D; Huang D; Keller TH; Sonntag S; Caflisch A; Vasudevan SG; Otting G
FEBS J; 2009 Aug; 276(15):4244-55. PubMed ID: 19583774
[TBL] [Abstract][Full Text] [Related]
40. Identification of structural determinants for inhibition strength and specificity of wheat xylanase inhibitors TAXI-IA and TAXI-IIA.
Pollet A; Sansen S; Raedschelders G; Gebruers K; Rabijns A; Delcour JA; Courtin CM
FEBS J; 2009 Jul; 276(14):3916-27. PubMed ID: 19769747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
